Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GIM-621
- Development stage
- Preclinical
- Lead developer
- Georgiamune
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
GIM-621 is a preclinical-stage, first-in-class oral small-molecule immunotherapy being developed for the treatment of multiple solid tumors. Discovered by Georgiamune, the candidate was generated from research into novel mechanisms governing immune activation, suppression, and homeostasis. In October 2026, Georgiamune entered into an exclusive worldwide license and collaboration agreement with Stemline Therapeutics, a subsidiary of the Menarini Group, to develop, manufacture, and commercialize GIM-621.
Beyond the preview
Go deeper on GIM-621.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GIM-621.